このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations

2026年9月28日 更新者:Xentria, Inc.

Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients with Pulmonary Sarcoidosis with or Without Extrapulmonary Manifestations

調査の概要

状態

積極的、募集していない

研究の種類

介入

入学 (推定)

32

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Alabama
      • Birmingham、Alabama、アメリカ、35233
        • Xentria Investigative Site
    • Colorado
      • Denver、Colorado、アメリカ、80206
        • Xentria Investigative Site
    • Florida
      • Jacksonville、Florida、アメリカ、32209
        • Xentria Investigative Site
    • Illinois
      • Chicago、Illinois、アメリカ、60611
        • Xentria Investigative Site
      • Chicago、Illinois、アメリカ、60612
        • Xentria Investigative Site
    • Iowa
      • Iowa City、Iowa、アメリカ、52242
        • Xentria Investigative Site
    • Maryland
      • Baltimore、Maryland、アメリカ、21287
        • Xentria Investigative Site
    • Michigan
      • Detroit、Michigan、アメリカ、48202
        • Xentria Investigative Site
    • Minnesota
      • Minneapolis、Minnesota、アメリカ、55455
        • Xentria Investigative Site
    • New York
      • Albany、New York、アメリカ、12208
        • Xentria Investigative Site
      • New York、New York、アメリカ、10029
        • Xentria Investigative Site
    • North Carolina
      • Greenville、North Carolina、アメリカ、27858
        • Xentria Investigative Site
    • Ohio
      • Cincinnati、Ohio、アメリカ、45267
        • Xentria Investigative Site
    • Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19140
        • Xentria Investigative Site
    • South Carolina
      • Charleston、South Carolina、アメリカ、29425
        • Xentria Investigative Site
    • Virginia
      • Charlottesville、Virginia、アメリカ、22903
        • Xentria Investigative Site
    • England
      • Coventry、England、イギリス、CV22DX
        • University Hospitals Coventry and Warwickshire NHS Trust
      • London、England、イギリス、SE59RS
        • King's College Hospital NHS Foundation Trust
      • London、England、イギリス、NW12PG
        • University College London Hospitals NHS Foundation Trust
      • Norwich、England、イギリス、NR47UY
        • Norfolk and Norwich University Hospitals NHS Foundation Trust
      • Oxford、England、イギリス、OX37LE
        • Oxford University Hospitals NHS Foundation Trust
    • Scotland
      • Perth、Scotland、イギリス、PH11NX
        • NHS Tayside
      • Barcelona、スペイン、08035
        • Xentria Investigative Site
      • Barcelona、スペイン、08036
        • Xentria Investigative Site
      • Seville、スペイン、41013
        • Xentria Investigative Site
      • Prague、チェコ、140 59
        • Xentria Investigative Site
      • Aalborg、デンマーク、9000
        • Xentria Investigative Site
      • Aarhus、デンマーク、8200
        • Xentria Investigative Site
      • Odense、デンマーク、5000
        • Xentria Investigative Site
      • Roskilde、デンマーク、4000
        • Xentria Investigative Site
      • Vejle、デンマーク、7100
        • Xentria Investigative Site
      • Bielsk Podlaski、ポーランド、15-044
        • Xentria Investigative Site
      • Lodz、ポーランド、90-153
        • Xentria Investigative Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~80年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Participant between 18 to 80 years (inclusive) of age.
  2. Weighs between 45 kg and 160 kg (99 to 353 lbs) at Screening.
  3. Diagnosis of pulmonary sarcoidosis (at least 6 months before Screening) using the 2020 American Thoracic Society (ATS) Clinical Practice Guideline (Crouser et al, 2020), the European Respiratory Society (ERS) or the WASOG criteria including a compatible clinical and radiologic presentation with other causes of granulomatous disease ruled out (cutaneous and ocular involvement permitted).
  4. Modified Medical Research Conference (mMRC) Dyspnea Scale of ≥ 1.
  5. Receiving treatment of 7.5 to 25 mg/day of oral prednisone, or equivalent, during the screening period and, at the determination of the investigator, is capable of undergoing the protocol specific corticosteroid taper regimen.
  6. Receiving treatment with methotrexate, azathioprine, mycophenolate, leflunomide, chloroquine, or hydroxychloroquine for at least 3 months before Screening that has been at a stable dose for 4 weeks before Screening. All efforts should be made to maintain stable background therapy at the Screening dose through the intervention period at the Investigator's discretion.
  7. Willing to refrain from consumption of grapefruit or grapefruit juice [pomelos, exotic citrus fruits, or grapefruit hybrids] from screening visit until after the final dose.
  8. Polymerase chain reaction (PCR) test or rapid antigen test negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Screening.
  9. Able to provide written informed consent.
  10. In the opinion of the Investigator, the participant is capable of understanding and complying with protocol requirements

Exclusion Criteria:

  1. Pregnant or breastfeeding women or women who are planning to become pregnant during the study.

  2. Participants > 65 years of age. (This exclusion criterion is only applicable for EU).

  3. Known potentially significant fibrotic disease and/or active inflammation contained solely in the hilar region as shown by high-resolution computed tomography (HRCT), confirmed by a central reader. Participants with current active inflammation in the hilar region with concurrent inflammation outside the hilar region may be included.

    A historical HRCT performed within 6 months of screening may be submitted for diagnostic confirmation by central review. If a subject's last HRCT was from > 6 months of screening, an HRCT should be performed during screening for diagnostic confirmation by central review.

  4. Any prior TNFα inhibitor therapy.

  5. Clinically significant extra-pulmonary sarcoidosis requiring systemic therapy as determined by the investigator.

  6. Baseline percent predicted forced vital capacity (FVC) of < 50%.

  7. Prior treatment with rituximab or repository corticotropin injection within the previous 12 months.

  8. Clinically significant Central Nervous System (CNS) sarcoidosis requiring therapy, except history of isolated seventh cranial nerve palsy or evidence of demyelinating neurologic disease.

  9. Advanced congestive heart failure (New York Heart Association [NYHA] 3 or 4).

  10. Current disease presentation consistent with Lofgren's syndrome (i.e., presence of the triad of erythema nodosum, bilateral hilar lymphadenopathy on chest X-ray, and joint pain).

  11. Clinically significant pulmonary hypertension requiring treatment. Note: Clinically significant pulmonary hypertension requiring treatment would be defined as treatment with, i.e., prostacyclins, phosphodiesterase 5 inhibitors, and endothelin receptor antagonists.

  12. Known hypersensitivity to any component of the formulation of XTMAB-16.

  13. Live or messenger ribonucleic acid (mRNA) vaccination within 2 weeks before Day 1 or inoculation with a live or mRNA vaccine is planned during study participation.

  14. Evidence of active or latent TB by interferon-gamma release assay (IGRA) or invasive fungal infections at Screening.

  15. Known positive history of malignancy other than non-melanomatous skin cancer in the last 2 years, including in-situ carcinoma of the uterine cervix completely cured by radical surgery.

  16. Positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, coronavirus disease (COVID-19), TB, or a known history of human immunodeficiency virus (HIV) infection at Screening.

  17. Women of childbearing potential who are sexually active with a non-sterilized male partner and are not willing to adhere to highly effective birth control measures from the time of signing the informed consent, throughout the duration of the study, and for 90 days after 5 half-lives have elapsed since the last dose of study drug.

  18. Male participants who are non-sterilized and sexually active with a female partner of childbearing potential and are not willing to use highly effective contraception from the time of signing the informed consent throughout the duration of the study, and for 90 days after 5 half-lives have elapsed since last dose of study drug.

  19. Clinically significant hepatic or renal disease, including uncontrolled diabetes at the discretion of the investigator.

  20. Any severe prior reaction to any type of biologics or human blood product such as albumin, IgG, etc.

  21. Concurrent emphysema.

  22. Known hypercalcemia due to non-sarcoidosis conditions such as untreated hyperparathyroidism, at the discretion of the investigator.

  23. Abnormal ECG: ventricular arrhythmias (non-sustained ventricular tachycardia (VT), multifocal or frequent premature ventricular contractions, bundle branch block, axis deviation, or abnormal Q waves). In the case of a QTcF (corrected QT interval by Fredericia) interval > 450 ms (men) or > 480 ms (women; participants with bundle branch block) or PR interval outside the range of 120 to 220 ms, the assessment may be repeated once for eligibility determination at Screening or Baseline.

  24. Donation or loss of 450 mL or more of his or her blood volume (including plasmapheresis) or transfusion of any blood product within 90 days prior to dosing.

  25. Known uncontrolled hypertension. Note: Uncontrolled hypertension is noted as blood pressure ≥ 160/100 mmHg despite antihypertensive therapy within 3 months of randomization.

  26. Clinical signs and symptoms consistent with COVID-19, e.g., fever, dry cough, dyspnea, sore throat, fatigue, new smell or taste disorder or confirmed infection by appropriate laboratory test within the last 4 weeks prior to Screening.

  27. In the opinion of the investigator, inability to tolerate corticosteroid taper.

  28. Concurrent systemic steroid use for non-sarcoidosis conditions.

  29. Concurrent known auto-immune disease requiring treatment.

  30. Participation in another clinical trial of an investigational agent within 3 months (small molecule) / 6 months (biologics) or 5 half-lives (if known) of the agent, whichever is longer.

  31. Any condition that required hospitalization within the 3 months prior to Day 1 or is likely to require so during the study.

  32. Clinically significant abnormalities in the Screening physical exam, medical history, vital signs, ECG, or clinical laboratory tests that are not known to be due to concurrent sarcoidosis, and in the opinion of the Investigator and Medical Monitor should preclude the participant's participation in the clinical study.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:順次割り当て
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:パート A - XTMAB-16: 2 mg/kg 4 週間ごと (Q4W) 12 週間またはプラセボ

Infusion

実験的:パート A - XTMAB-16: 4 mg/kg 4 週間ごと (Q4W) 12 週間またはプラセボ

Infusion

実験的:パート A - XTMAB-16: 2 mg/kg 2 週間ごと (Q2W) 12 週間またはプラセボ

Infusion

実験的:パート A - XTMAB-16: 4 mg/kg 2 週間ごと (Q2W) 12 週間またはプラセボ

Infusion

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Rate of Adverse Events (AEs), including Serious Adverse Events (SAEs), Dose Limiting Toxicities (DLTs), and Adverse Events of Special Interests (AESIs) throughout the study duration
時間枠:Throughout Study Duration, 20 weeks

To evaluate the safety and tolerability of multiple ascending doses of XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Throughout Study Duration, 20 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Pharmacokinetic (PK) profile including trough concentration (Ctrough)
時間枠:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Pharmacokinetic (PK) profile including maximum concentration (Cmax)
時間枠:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Pharmacokinetic (PK) profile including average concentration (Caverage)
時間枠:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Pharmacokinetic (PK) profile including area under the curve (AUC)
時間枠:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Dose normalized maximum serum concentration (Cmax/D)
時間枠:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Dose normalized area under the concentration time curve over the dosing interval (AUCtau/D)
時間枠:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Dose normalized area under the concentration time curve from time 0 to the time of the last quantifiable concentration observed (AUClast/D)
時間枠:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Dose normalized area under the concentration time curve from time 0 extrapolated to infinity (AUCinf/D)
時間枠:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Pharmacodynamics (PD) markers, including: Angiotensin converting enzyme (ACE), Soluble IL-2 receptor (sIL 2R), C-reactive protein (CRP), Interleukin-1b (IL-1b) and Calcitriol (vitamin D 1, 25)
時間枠:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Occurrence and persistence of anti-drug antibodies (ADA)
時間枠:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Mean percent change in forced vital capacity (FVC)%
時間枠:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Change in King's Sarcoidosis Questionnaire (KSQ) - Lung Score
時間枠:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
The King's Sarcoidosis Questionnaire (KSQ) - General Health. Results are given as a number between 1 to 100 with higher numbers indicating better health. The minimal clinically important difference (MCID) for KSQ remains unclear in sarcoidosis.
時間枠:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
The Leicester Cough Questionnaire items are scored on a 7-point Likert scale. A total score (range 3 to 21) is also calculated by adding the domain scores together, with higher scores indicating better quality of life. The MCID for chronic cough is 1.3.
時間枠:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
The Steroid Toxicity Questionnaire (STQ) is a simple 12 question tool used to characterize the toxicity associated with steroid use using a 4-point scale. The MCID remains unclear in sarcoidosis. Higher scores indicate greater steroid toxicity
時間枠:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Observed dose limiting toxicities (DLT), rate of adverse events of special interest (AESI) throughout the study duration between dose levels and frequencies
時間枠:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Proportion of participants who achieve the targeted tapered dose of corticosteroid
時間枠:Baseline to Week 12

To observe the potential therapeutic effect of XTMAB-16 as measured by the ability to reduce background oral corticosteroid use

Baseline to Week 12
Proportion of participants who achieve at least 50% reduction in dose of corticosteroid by Week 12
時間枠:Baseline to Week 12

To observe the potential therapeutic effect of XTMAB-16 as measured by the ability to reduce background oral corticosteroid use

Baseline to Week 12
Total (systemic) clearance after intravenous (IV) dose in the intended participant population
時間枠:Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Volume of distribution after intravenous (IV) dose and an estimate of the volume of distribution at steady state based on single dose IV data parameters in the intended participant population
時間枠:Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Terminal elimination phase half-life expressed in time units in the intended participant population
時間枠:Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Accumulation ratio repeat dosing
時間枠:Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Area under the effect-time curve from time 0 (predose) to the last quantifiable effect -concentration time point, t (AUEC0-t)
時間枠:Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Maximum observed effect (Emax, obs)
時間枠:Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Time to reach Emax, obs (tEmax, obs)
時間枠:Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Absolute and percent change in biomarkers from Baseline to End of Infusion (EOI), Interleukin-6 (IL-6) and Soluble Tumor Necrosis Factor α (sTNFα)
時間枠:Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Number and percentage of participants by cohort who test positive for XTMAB-16 anti-drug antibodies (ADA) and transient & persistent positive status at follow-up assessments
時間枠:Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Number and percentage of participants by cohort who test positive for XTMAB-16 neutralizing antibody (nAb) and transient & persistent positive status at follow-up assessments
時間枠:Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年11月10日

一次修了 (推定)

2026年10月31日

研究の完了 (推定)

2026年10月31日

試験登録日

最初に提出

2023年5月12日

QC基準を満たした最初の提出物

2023年5月25日

最初の投稿 (実際)

2023年6月6日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月2日

QC基準を満たした最後の更新が送信されました

2026年9月28日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する